Adding the FcRn antagonist efgartigimod for the prevention of IgG ‐mediated complications in the peri‐transplant period
Transfusion · 2025
DOI: 10.1111/trf.18374 ↗Kurz gefasst
Fallbericht in der Zeitschrift Transfusion, 2025. Verfasst von Dennis L Cooper und 19 weiteren Autor:innen. Beteiligte Einrichtung: Montefiore Einstein Comprehensive Cancer Center. Albert Einstein College of Medicine, Bronx, New York, USA. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Histocompatibility Antigens Class I, Immunoglobulin G, Receptors, Fc. Die Arbeit nennt 15 Literaturangaben.
Abstract (Originalsprache)
Background
The management of IgG‐mediated diseases in the peri‐allogeneic transplant period remains challenging. Specifically, the presence of donor‐specific antibodies (DSA) is a major cause of graft failure and poor graft function; despite improvements in desensitization, it remains an unmet need. Similarly, there is no standard approach for the prevention of delayed RBC transfusion independence and pure red blood cell aplasia caused by IgG isoagglutinins after major ABO‐mismatched transplant. We describe the first use of the FcRn antagonist efgartigimod to assist in preventing both issues in a patient with high DSA undergoing major ABO‐mismatched transplant. Case Report A woman with molecular relapse of FLT3‐ITD+ AML with no available haploidentical donors and a poor donor search underwent a myeloablative stem cell transplant from a major ABO‐mismatched (A donor into O recipient), 6/8 HLA‐matched unrelated donor. Prior to conditioning chemotherapy, DSA remained above a median fluorescent intensity (MFI) of 8000 despite rituximab, daratumumab, IVIG, and plasma exchange. Efgartigimod was given on days −3, +4, and +11 of transplant, resulting in a prompt decrease of DSA and anti‐A isohemagglutinins and successful engraftment, including rapid RBC transfusion independence.
Discussion
Desensitization strategies for patients with high DSA or high isohemagglutinins remain imperfect and time consuming. The use of FcRn antagonists such as efgartigimod, which reduce recycling of IgG, including pathogenic IgG antibodies, complements the plasma and lymphocyte depleting activity of conditioning therapy and posttransplant cyclophosphamide and may be an effective adjunct in the management of IgG‐mediated processes in the posttransplant period.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Montefiore Einstein Comprehensive Cancer Center. Albert Einstein College of Medicine, Bronx, New York, USA.
- Department of Surgery, Montefiore Medical Center, Bronx, New York, USA.
- Department of Pathology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA.
ORCID-Profile: Dennis L Cooper, Monika Paroder, Lauren C Shapiro
Zitieren
APA
Cooper, D. L., Verceles, J. A., Kheradmand, T., Paroder, M., Lombardo, A., de Castro, A., Browne, R., Konopleva, M., Moavero, B., Goldfinger, M., Mantzaris, I., Kornblum, N., Sica, R. A., Shastri, A., Shapiro, L. C., Peeke, S. Z., Gupta, R., Gritsman, K., Feldman, E. J., & Verma, A. (2025). Adding the FcRn antagonist efgartigimod for the prevention of IgG ‐mediated complications in the peri‐transplant period. Transfusion. https://doi.org/10.1111/trf.18374
Vancouver
Cooper DL, Verceles JA, Kheradmand T, Paroder M, Lombardo A, de Castro A, et al. Adding the FcRn antagonist efgartigimod for the prevention of IgG ‐mediated complications in the peri‐transplant period. Transfusion. 2025. doi:10.1111/trf.18374
BibTeX
@article{Cooper2025,
author = {Cooper, Dennis L and Verceles, Jhannine Alyssa and Kheradmand, Taba and Paroder, Monika and Lombardo, Amanda and de Castro, Alyssa and Browne, Roy and Konopleva, Marina and Moavero, Brittany and Goldfinger, Mendel and Mantzaris, Ioannis and Kornblum, Noah and Sica, Roberto A and Shastri, Aditi and Shapiro, Lauren C and Peeke, Stephen Z and Gupta, Ridhi and Gritsman, Kira and Feldman, Eric J and Verma, Amit},
title = {Adding the FcRn antagonist efgartigimod for the prevention of IgG ‐mediated complications in the peri‐transplant period},
journal = {Transfusion},
year = {2025},
doi = {10.1111/trf.18374}
}
EUVIMED